Neoadjuvant DPX-Survivac Aromatase Inhibition Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

  • STATUS
    Recruiting
  • End date
    Jun 1, 2026
  • participants needed
    18
  • sponsor
    Providence Health & Services
Updated on 4 November 2021
cyclophosphamide
immunohistochemistry
HER2
erbb2
aromatase inhibitor
letrozole
mammogram
her2/neu-negative breast cancer
ki-67

Summary

The study seeks to establish the safety of neoadjuvant aromatase inhibitor with: DPX-Survivac, DPX-Survivac plus radiation, or DPX-Survivac with cyclophosphamide in stage I to III HR+HER2- breast cancer. There will be sequential enrollment into 3 arms with an anticipated N=6 participants per arm for N=18 participants in total. All participants will receive letrozole 2.5 mg daily during the 6 weeks of neoadjuvant therapy. Neoadjuvant therapy occurs weeks 1-6, with standard of care surgery taking place week 7 to 9.

Description

Women with hormone receptor positive, HER2-negative (HR+/HER2-) breast cancer with large tumors or positive lymph nodes have low response rates with neoadjuvant chemotherapy. Survivin is overexpressed in HR+HER2- breast cancer. Increasing tumor-specific Th1 immunity by administration of DPX-Survivac may alter the immune environment of these tumors. Radiation is a standard component of breast cancer therapy causing a reduction in local recurrences and improved breast cancer specific survival. Low dose cyclophosphamide can deplete regulatory T-cells without altering levels of effector T-cells. The investigators predict that combining a vaccine targeting Survivin, overexpressed in HR+HER2- tumors, with other immune modulating therapies such as radiation or low dose cyclophosphamide can enhance the efficacy of DPX-Survivac.

Primary Objective

  1. Safety of neoadjuvant aromatase inhibitor with: DPX-Survivac, DPX-Survivac plus radiation, or DPX-Survivac with cyclophosphamide in stage I to III HR+HER2- breast cancer Secondary Objectives
    1. Immunogenicity of each arm, assessed by IFN- ELISPOT in PBMC.
    2. Immunogenicity of each arm, assessed by GEO-Mx digital spatial profiler evaluation of FFPE tissue and TCR evaluation for surviving-specific T cells in the tumor.

Exploratory Objectives

  1. Evaluation of the % TIL in the biopsy specimen and at the time of surgery within/between arms
  2. Evaluation of the Ki67 changes between the biopsy and at time of surgery within/between arms
  3. Comparison of immunogenicity, TIL change, and Ki67 change across arms
  4. Epitope spreading within/between arms
  5. Evaluation of Triseq (germline, whole exome sequencing, and RNAseq) of the tumor immune environment within/between arms
  6. Evaluation of immune environment using multi-parameter immunohistochemistry within/between arms
  7. Evaluation by experimental MRI in arm that adds radiation
  8. Evaluation of survivin-specific MHC-tetramer staining in PBMC

Details
Condition breast carcinoma, Breast Cancer, Breast Cancer Diagnosis, cancer, breast
Treatment DPX-Survivac, Cyclophosphamide 50mg, Letrozole 2.5mg, XRT 10Gy x2
Clinical Study IdentifierNCT04895761
SponsorProvidence Health & Services
Last Modified on4 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must provide informed consent prior to any study-specific procedures and be able to understand and be willing to sign an informed consent document. Results of standard-of-care tests or examinations performed prior to obtaining informed consent and prior to treatment may be used for screening assessments rather than repeating such evaluations if within 30 day of day 1
Women with resectable, non-metastatic breast cancer that is >1 cm, hormone receptor positive, HER2 negative, Ki67>10%
HER2 negative is defined as
-1+ HER2 expression by immunohistochemistry (IHC) OR Fluorescence in situ
hybridization (FISH) negative OR HER2 2+ and FISH negative
\. Patients must be at least 28 days post systemic steroids prior to
enrollment
\. Patients must be at least 18 years of age
\. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance
Status Score of 1
\. Adequate laboratory values within 30 days of enrollment defined as
follows
White blood cell (WBC) 3000/mm3
Hemoglobin (Hgb) 9 g/dL
Neutrophil count 1500/mm3
Lymphocyte count 1000/mm3
Platelet count 75,000/mm3
Serum creatinine 2.0 mg/dL or creatinine clearance > 60 ml/min
Total bilirubin 1.5 mg/dL
Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) 2 times the ULN-
Patients must have recovered from major infections and, in the opinion of the investigator, do not have any significant active concurrent medical illnesses precluding protocol treatment
The effects of DPX-Survivac on the developing human fetus are unknown. Women on the trial should be post-menopausal based on the NCCN definition of menopause
For patients in Arm B only, they must be able to undergo MR imaging as determined by treating physician using the standard Radiation Oncology MR screening process

Exclusion Criteria

Patients may not be receiving any other investigational agents or on concurrent clinical trials while on during the clinical trial period
History of allergic reactions attributed to compounds of similar chemical or biologic composition to DPX-Survivac
Pregnant and pre-menopausal women are excluded from this study because to keep anti-endocrine therapy consistent between patients
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Uncontrolled autoimmune disease. Autoimmune disease allowed if controlled (with or without treatment) for the last 12 months
Patients may not have received or plan to receive neoadjuvant systemic chemotherapy
Patients unable to receive an aromatase inhibitor
Prior radiation to the affected breast 9) Previous cancers except for non-melanoma skin cancers or high risk cervical lesions in the past 5 years
Previous breast cancer, tamoxifen, or aromatase inhibitor use. 11) Previous investigational immune therapy use-
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note